JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: SHR0302 is a novel, highly potent and orally bioavailable inhibitor of the JAK family imembers, with high selectivity for JAK1. The selectivity of SHR0302 for JAK1 is > 10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. SHR0302 inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. SHR0302 has anti-proliferative and anti-inflammatory effects by blocking JAK/STAT3 signaling, suppressing proliferation, migration andcollagen production, and inducing the apoptosis of hepatic stellatecells..
References:
1. HuaxunWu, et al. JAK1-STAT3 Blockade by JAK Inhibitor SHR0302 AttenuatesInflammatory Responses of Adjuvant-Induced Arthritis Rats and DecreasesTh17 and Total B Cells. Joint Bone Spine. 2016 Oct; 83(5):525-32.
2. Yuan-JingGu, et al. Targeted Blockade of JAK/STAT3 Signaling InhibitsProliferation, Migration and Collagen Production as Well as Inducing theApoptosis of Hepatic Stellate Cells. Int J Mol Med. 2016Sep; 38(3):903-11.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Delivery expected until 9/6/2024
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!